Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Does sequencing order of antiandrogens in prostate cancer matter?

Nature Reviews Urology volume 17, pages 197–198 (2020)Cite this article

Subjects

The optimal treatment sequences to maximize the clinical benefit for patients with metastatic castration-resistant prostate cancer (mCRPC) have not been defined. A new prospective, randomized trial on optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in mCRPC investigated whether one regimen resulted in superior outcomes.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Khalaf, D. J. et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 20, 1730–1739 (2019).

    Article  CAS  Google Scholar 

  2. Terada, N. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: the Kyoto-Baltimore collaboration. Int. J. Urol. 24, 441–448 (2017).

    Article  CAS  Google Scholar 

  3. Brasso, K. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur. Urol. 68, 317–324 (2015).

    Article  CAS  Google Scholar 

  4. Maughan, B. L. & Antonarakis, E. S. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin. Pharmacother. 16, 1521–1537 (2015).

    Article  CAS  Google Scholar 

  5. Isaacsson Velho, P. et al. Wnt-pathway activating mutations are associated with resistance to first-line abiraterone and enzalutamide in castration-resistant prostate cancer. Eur. Urol. 77, 14–21 (2020).

    Article  CAS  Google Scholar 

  6. Annala, M. et al. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov. 8, 444–457 (2018).

    Article  CAS  Google Scholar 

  7. Hussain, M. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J. Clin. Oncol. 24, 3984–3990 (2006).

    Article  Google Scholar 

  8. Harshman, L. C. et al. Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel. J. Clin. Oncol. 36, 376–382 (2018).

    Article  CAS  Google Scholar 

  9. de Wit, R. et al. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N. Engl. J. Med. 381, 2506–2518 (2019).

    Article  Google Scholar 

  10. Eisenberger, M. A. & Antonarakis, E. S. Hormonal therapy or chemotherapy for metastatic prostate cancer - playing the right CARD. N. Engl. J. Med. 381, 2564–2566 (2019).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank the National Institutes of Health Cancer Center Support Grant P30CA006973 (to E.S.A) for partially supporting this work

Author information

Authors and Affiliations

  1. Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT, USA

    Benjamin L. Maughan

  2. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Emmanuel S. Antonarakis

Authors
  1. Benjamin L. Maughan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Emmanuel S. Antonarakis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel S. Antonarakis.

Ethics declarations

Competing interests

B.L.M is a paid consultant and/or advisor to Janssen, Astellas, Bristol-Myers Squibb, Clovis, Tempus, Merck, Bayer, Exelixis and Peloton Therapeutics; and he has received research funding to his institution from Exelixis, Bavarian-Nordic and Bristol-Myers Squibb. E.S.A. is a paid consultant and/or advisor to Janssen, Astellas, Sanofi, Dendreon, Pfizer, Amgen, AstraZeneca, Bristol-Myers Squibb, Clovis and Merck; he has received research funding to his institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Bristol Myers-Squibb, AstraZeneca, Clovis and Merck; and he is the co-inventor of a biomarker technology that has been licensed to Qiagen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maughan, B.L., Antonarakis, E.S. Does sequencing order of antiandrogens in prostate cancer matter?. Nat Rev Urol 17, 197–198 (2020). https://doi.org/10.1038/s41585-020-0289-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-020-0289-9

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer